Document is current
Any future updates will be listed below
-
Authors
Rafei, Hind https://orcid.org/0000-0002-5724-4183
Basar, Rafet https://orcid.org/0000-0003-4713-0454
Acharya, Sunil https://orcid.org/0000-0002-3907-9321
Hsu, Yu-Sung
Liu, Pinghua
Zhang, Deqiang
Bohn, Toszka
Liang, Qingnan
Mohanty, Vakul https://orcid.org/0000-0002-5536-6750
Upadhyay, Ranjan https://orcid.org/0000-0002-1326-5898
Li, Ping
Phadatare, Pravin
Dede, Merve https://orcid.org/0000-0002-0868-5863
Xiong, Donghai
Fan, Huihui https://orcid.org/0000-0003-4233-5389
Jones, Corry Mathew
Kunz, Sebastian https://orcid.org/0000-0002-8897-3215
Daher, May https://orcid.org/0000-0002-6026-8397
Nunez Cortes, Ana Karen
Shanley, Mayra
Liu, Bin
Moseley, Sadie Mae
Zhang, Chenyu
Fang, Dexing https://orcid.org/0009-0003-9328-1250
Banerjee, Pinaki
Uprety, Nadima
Li, Ye https://orcid.org/0000-0001-7727-0875
Shrestha, Rejeena
Wan, Xinhai
Shen, Hong
Woods, Vernikka
Gilbert, April Lamour
Rawal, Seema
Dou, Jinzhuang
Tan, Yukun https://orcid.org/0000-0002-6368-8653
Park, Jeong-Min https://orcid.org/0000-0003-3056-2314
Reyes Silva, Francia
Biederstädt, Alexander https://orcid.org/0000-0003-2805-8231
Kaplan, Mecit
Jiang, Xin Ru
Biederstädt, Inci
Kumar, Bijender
Tiberti, Silvia https://orcid.org/0000-0003-2141-2365
Moore, Madison
Jin, Jingling
Yang, Ryan Z.
Muniz-Feliciano, Luis
Rosemore, Samuel
Lin, Paul
Deyter, Gary M.
Fowlkes, Natalie Wall
Jain, Abhinav K. https://orcid.org/0000-0003-3268-514X
Marin, David
Maitra, Anirban https://orcid.org/0000-0001-7923-9978
Chen, Ken https://orcid.org/0000-0003-4013-5279
Bopp, Tobias https://orcid.org/0000-0002-3232-8065
Shpall, Elizabeth J.
Rezvani, Katayoun https://orcid.org/0000-0002-9599-2246
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 30 April 2025
First Online: 4 June 2025
Competing interests
: H.R., R.B., S.A., M.S., M. Daher, P.B., N.U., Y.L., P. Lin, D.M., E.J.S. and K.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical. S.A., R.B., D.M., E.J.S. and K.R. have an institutional financial conflict of interest with Affimed. A.M. is listed as an inventor on a patent that has been licensed by Johns Hopkins University to ThriveEarlier Detection. A.M. serves as a consultant for Tezcat Biotechnology. A.M. receives royalties from a patent that is licensed to Exact Sciences. K.R. participates on the Scientific Advisory Board for Avenge Bio, Virogin Biotech, Navan Technologies, Caribou Biosciences, Bit Bio, Replay, oNKo Innate, The Alliance for Cancer Gene Therapy ACGT, Innate Pharma and Shinobi Therapeutics. K.R. is the scientific founder of Syena. E.J.S. participates on the Scientific Advisory Board for Adaptimmune Limited, Axio Research, Celaid Therapeutics, FibroBiologics, Navan Technologies, New York Blood Center and Zelluna Immunotherapy. M. Daher participates on the Scientific Advisory Board of Cellsbin. The remaining authors declare that they have no competing interests.
